# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 17, "Arch Intern Med .", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasJournal> \"Arch Intern Med .\"."
1, PublicationYear, 18, 22, "2009", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasPublicationYear> \"2009\"."
69, Title, 101, 235, "Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus .", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasTitle> \"Long - term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus .\"."
2, Metformin, 124, 133, "metformin", "", 
3, Type2Diabetes, 209, 233, "type 2 diabetes mellitus", "", 
4, Author, 236, 242, "Kooy A", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasAuthor> \"Kooy A\"."
5, Author, 251, 261, "de Jager J", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasAuthor> \"de Jager J\"."
6, Author, 264, 272, "Lehert P", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasAuthor> \"Lehert P\"."
7, Author, 275, 281, "Bets D", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasAuthor> \"Bets D\"."
8, Author, 284, 296, "Wulffel é MG", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasAuthor> \"Wulffel é MG\"."
9, Author, 299, 308, "Donker AJ", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasAuthor> \"Donker AJ\"."
10, Author, 311, 323, "Stehouwer CD", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasAuthor> \"Stehouwer CD\"."
77, Netherlands, 444, 455, "Netherlands", "", "<http://ctro/data#Population_59986> <http://ctro/data#hasCountry> <http://ctro/data#Netherlands>."
81, ObjectiveDescription, 660, 826, "We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) .", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#hasObjectiveDescription> \"We investigated whether metformin hydrochloride has sustained beneficial metabolic and ( cardio ) vascular effects in patients with type 2 diabetes mellitus ( DM2 ) .\"."
12, Metformin, 684, 707, "metformin hydrochloride", "", 
13, Type2Diabetes, 792, 816, "type 2 diabetes mellitus", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
14, Type2Diabetes, 819, 822, "DM2", "", 
15, NumberPatientsCT, 848, 851, "390", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#hasNumberPatientsCT> \"390\"."
18, Precondition, 852, 881, "patients treated with insulin", "", "<http://ctro/data#Population_59986> <http://ctro/data#hasPrecondition> \"patients treated with insulin\"."
24, Insulin, 874, 881, "insulin", "", 
17, Multicenter, 911, 922, "3 hospitals", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
16, Randomized, 928, 938, "randomized", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
86, Placebo, 941, 948, "placebo", "", 
137, Duration, 997, 1008, "4 . 3 years", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#hasCTduration> \"4 . 3 years\"."
19, Metformin, 1018, 1041, "metformin hydrochloride", "", 
20, DoseValue, 1044, 1047, "850", "", "<http://ctro/data#Medication_60032> <http://ctro/data#hasDoseValue> \"850\"."
21, mg, 1048, 1050, "mg", "", "<http://ctro/data#Medication_60032> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
22, Placebo, 1056, 1063, "placebo", "", "<http://ctro/data#Medication_60039> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
23, Frequency, 1066, 1083, "1 - 3 times daily", "", "<http://ctro/data#Intervention_60046> <http://ctro/data#hasFrequency> \"1 - 3 times daily\". <http://ctro/data#Intervention_60052> <http://ctro/data#hasFrequency> \"1 - 3 times daily\"."
25, Insulin, 1099, 1106, "insulin", "", 
144, EndPointDescription, 1159, 1214, "microvascular and macrovascular morbidity and mortality", "", 
145, EndPointDescription, 1247, 1302, "microvascular and macrovascular morbidity and mortality", "", 
146, EndPointDescription, 1265, 1302, "macrovascular morbidity and mortality", "", 
26, HbA1c, 1361, 1380, "hemoglobin A ( 1c )", "", 
27, HbA1c, 1383, 1393, "HbA ( 1c )", "", 
52695, InsulinDose, 1398, 1417, "insulin requirement", "", 
28, EndPointDescription, 1420, 1432, "lipid levels", "", 
29, BloodPressure, 1435, 1449, "blood pressure", "", 
30, BodyWeight, 1452, 1463, "body weight", "", 
31, BMI, 1470, 1485, "body mass index", "", 
32, Metformin, 1512, 1521, "Metformin", "", 
52689, WeightGain, 1542, 1553, "weight gain", "", "<http://ctro/data#Endpoint_59994> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#WeightGain>."
101, Mean, 1556, 1560, "mean", "", "<http://ctro/data#Mean_59996> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_59994> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_59996>."
102, WeightGain, 1561, 1572, "weight gain", "", 
38, Reduction, 1577, 1583, "3 . 07", "", "<http://ctro/data#Outcome_60058> <http://ctro/data#hasChangeValue> \"3 . 07\"."
36, Kg, 1584, 1586, "kg", "", "<http://ctro/data#Endpoint_59994> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
37, Kg, 1618, 1620, "kg", "", 
105, PValueResValue, 1625, 1634, "P < . 001", "", "<http://ctro/data#Outcome_60058> <http://ctro/data#hasPValueResValue> \"P < . 001\"."
106, Mean, 1667, 1671, "mean", "", "<http://ctro/data#Mean_60001> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_59999> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_60001>."
34, HbA1c, 1685, 1701, "HbA ( 1c ) level", "", "<http://ctro/data#Endpoint_59999> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
40, Reduction, 1704, 1709, "0 . 4", "", "<http://ctro/data#Outcome_60085> <http://ctro/data#hasChangeValue> \"0 . 4\"."
39, Percentage, 1710, 1711, "%", "", "<http://ctro/data#Endpoint_59999> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
41, ConfIntervalChangeValue, 1731, 1756, "95 % CI , 0 . 55 - 0 . 25", "", "<http://ctro/data#Outcome_60085> <http://ctro/data#hasConfIntervalChangeValue> \"95 % CI , 0 . 55 - 0 . 25\"."
42, PValueChangeValue, 1761, 1770, "P < . 001", "", "<http://ctro/data#Outcome_60085> <http://ctro/data#hasPValueChangeValue> \"P < . 001\"."
154, InsulinDose, 1891, 1911, "insulin requirements", "", "<http://ctro/data#InsulinDose_60005> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#InsulinDose>. <http://ctro/data#Endpoint_60004> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#InsulinDose_60005>."
114, Mean, 1914, 1918, "mean", "", "<http://ctro/data#Mean_60006> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_60004> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_60006>."
43, Reduction, 1931, 1938, "19 . 63", "", "<http://ctro/data#Outcome_60112> <http://ctro/data#hasChangeValue> \"19 . 63\"."
155, Int_Unit, 1939, 1941, "IU", "", "<http://ctro/data#Endpoint_60004> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Int_Unit>."
156, Frequency, 1944, 1945, "d", "", 
44, ConfIntervalChangeValue, 1948, 1975, "95 % CI , 24 . 91 - 14 . 36", "", "<http://ctro/data#Outcome_60112> <http://ctro/data#hasConfIntervalChangeValue> \"95 % CI , 24 . 91 - 14 . 36\"."
157, Int_Unit, 1976, 1978, "IU", "", 
52694, Interval, 1981, 1982, "d", "", 
45, PValueChangeValue, 1987, 1996, "P < . 001", "", "<http://ctro/data#Outcome_60112> <http://ctro/data#hasPValueChangeValue> \"P < . 001\"."
46, Metformin, 2001, 2010, "Metformin", "", 
60, EndPointDescription, 2146, 2169, "macrovascular end point", "", "<http://ctro/data#EndPointDescription_60010> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_60009> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_60010>."
126, AggregationMethod, 2172, 2184, "hazard ratio", "", "<http://ctro/data#AggregationMethod_60011> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AggregationMethod>. <http://ctro/data#Endpoint_60009> <http://ctro/data#hasAggregationMethod> <http://ctro/data#AggregationMethod_60011>."
48, ResultMeasuredValue, 2187, 2193, "0 . 61", "", "<http://ctro/data#Outcome_60139> <http://ctro/data#hasResultMeasuredValue> \"0 . 61\"."
47, ConfIntervalResValue, 2196, 2221, "95 % CI , 0 . 40 - 0 . 94", "", "<http://ctro/data#Outcome_60139> <http://ctro/data#hasConfIntervalResValue> \"95 % CI , 0 . 40 - 0 . 94\"."
49, PValueResValue, 2224, 2232, "P = . 02", "", "<http://ctro/data#Outcome_60139> <http://ctro/data#hasPValueResValue> \"P = . 02\"."
128, EndPointDescription, 2334, 2357, "macrovascular end point", "", 
54, Metformin, 2414, 2423, "Metformin", "", 
147, ConclusionComment, 2414, 2576, "Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point .", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#hasConclusionComment> \"Metformin , added to insulin in patients with DM2 , improved body weight , glycemic control , and insulin requirements but did not improve the primary end point .\"."
57, Insulin, 2435, 2442, "insulin", "", 
55, Type2Diabetes, 2460, 2463, "DM2", "", 
56, BodyWeight, 2475, 2486, "body weight", "", 
52696, InsulinDose, 2512, 2532, "insulin requirements", "", 
58, Metformin, 2577, 2586, "Metformin", "", 
148, ConclusionComment, 2577, 2687, "Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years .", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#hasConclusionComment> \"Metformin did , however , reduce the risk of macrovascular disease after a follow - up period of 4 . 3 years .\"."
52697, ObservedResult, 2603, 2643, "reduce the risk of macrovascular disease", "", 
59, EndPointDescription, 2622, 2643, "macrovascular disease", "", 
138, Duration, 2674, 2685, "4 . 3 years", "", 
149, ConclusionComment, 2688, 2858, "These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated .", "", "<http://ctro/data#ClinicalTrial_59967> <http://ctro/data#hasConclusionComment> \"These sustained beneficial effects support the policy to continue metformin treatment after the introduction of insulin in any patient with DM2 , unless contraindicated .\"."
61, Metformin, 2754, 2763, "metformin", "", 
62, Insulin, 2800, 2807, "insulin", "", 
63, Type2Diabetes, 2828, 2831, "DM2", "", 
64, PMID, 2977, 2985, "19307526", "", "<http://ctro/data#Publication_59954> <http://ctro/data#hasPMID> \"19307526\"."
